All In Biotech

Drug Trial Radar · NCT01785875

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

Last checked: Nov 20, 2026Latest source record: Apr 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

891

Actual

Start

Jul 31, 2013

Primary completion

Jul 1, 2015

Study completion Jul 1, 2015

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG 416) for the treatment of SHPT in adults with CKD on hemodialysis.

Conditions

  • Hyperparathyroidism, Secondary

Interventions

  • EtelcalcetideDrug

    Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: From first dose until 30 days after last dose; the treatment period was 52 weeks.
  2. Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4Time frame: 52 weeks
  3. Number of Participants Who Developed Anti-etelcalcetide AntibodiesTime frame: Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit
  4. Change From Baseline in Blood PressureTime frame: Baseline and Weeks 24 and 48

Locations

208 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Pine Bluff, Arkansas

  • Research Site

    Azusa, California

  • Research Site

    Bakersfield, California

  • Research Site

    Chula Vista, California

  • Research Site

    Cudahy, California

  • Research Site

    Fairfield, California

  • Research Site

    Glendale, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site

    Northridge, California

  • Research Site

    Norwalk, California

  • Research Site

    Ontario, California

  • Research Site

    Riverside, California

  • Research Site

    San Gabriel, California

  • Research Site

    Simi Valley, California

  • Research Site

    Whittier, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Stamford, Connecticut

  • Research Site

    Coral Springs, Florida

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Pinecrest, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    Evanston, Illinois

  • Research Site

    Gurnee, Illinois

  • Research Site

    Merrillville, Indiana

  • Research Site

    Michigan City, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Lafayette, Louisiana

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.